GSK.L vs. SWDA.L
Compare and contrast key facts about GlaxoSmithKline plc (GSK.L) and iShares Core MSCI World UCITS ETF USD (Acc) (SWDA.L).
SWDA.L is a passively managed fund by iShares that tracks the performance of the MSCI ACWI NR USD. It was launched on Sep 25, 2009.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK.L or SWDA.L.
Key characteristics
GSK.L | SWDA.L | |
---|---|---|
YTD Return | 6.03% | 16.36% |
1Y Return | 3.26% | 22.70% |
3Y Return (Ann) | 6.17% | 10.10% |
5Y Return (Ann) | 2.46% | 12.72% |
10Y Return (Ann) | 5.95% | 13.05% |
Sharpe Ratio | 0.19 | 2.29 |
Sortino Ratio | 0.37 | 3.15 |
Omega Ratio | 1.05 | 1.43 |
Calmar Ratio | 0.19 | 3.86 |
Martin Ratio | 0.46 | 16.30 |
Ulcer Index | 8.36% | 1.44% |
Daily Std Dev | 20.34% | 10.25% |
Max Drawdown | -50.10% | -25.58% |
Current Drawdown | -15.98% | -0.22% |
Correlation
The correlation between GSK.L and SWDA.L is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GSK.L vs. SWDA.L - Performance Comparison
In the year-to-date period, GSK.L achieves a 6.03% return, which is significantly lower than SWDA.L's 16.36% return. Over the past 10 years, GSK.L has underperformed SWDA.L with an annualized return of 5.95%, while SWDA.L has yielded a comparatively higher 13.05% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK.L vs. SWDA.L - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and iShares Core MSCI World UCITS ETF USD (Acc) (SWDA.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GSK.L vs. SWDA.L - Dividend Comparison
GSK.L's dividend yield for the trailing twelve months is around 4.01%, while SWDA.L has not paid dividends to shareholders.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
GlaxoSmithKline plc | 4.01% | 3.84% | 4.66% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% | 5.76% | 5.62% |
iShares Core MSCI World UCITS ETF USD (Acc) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
GSK.L vs. SWDA.L - Drawdown Comparison
The maximum GSK.L drawdown since its inception was -50.10%, which is greater than SWDA.L's maximum drawdown of -25.58%. Use the drawdown chart below to compare losses from any high point for GSK.L and SWDA.L. For additional features, visit the drawdowns tool.
Volatility
GSK.L vs. SWDA.L - Volatility Comparison
GlaxoSmithKline plc (GSK.L) has a higher volatility of 6.45% compared to iShares Core MSCI World UCITS ETF USD (Acc) (SWDA.L) at 2.38%. This indicates that GSK.L's price experiences larger fluctuations and is considered to be riskier than SWDA.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.